Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALMA CRUZ SANTANA

Allopathic & Osteopathic Physicians Dermatology

NPI
1447364716
CMS profile
945487
Location
CAROLINA, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,010.96

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,846.01 55
Consulting Fee $1,100.00 1
Education $64.95 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALMA CRUZ SANTANA

NPI 1447364716 · CMS profile ID 945487

Allopathic & Osteopathic Physicians / Dermatology

CAROLINA, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALMA CRUZ SANTANA, NPI 1447364716, CMS profile ID 945487. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALMA CRUZ SANTANA, NPI 1447364716, CMS profile ID 945487. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALMA CRUZ SANTANA, NPI 1447364716, CMS profile ID 945487, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $3,010.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–57 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $41.6802/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136027372 CMS
Eli Lilly Export S.A. Puerto Rico Branch $22.5002/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136027368 CMS
Novartis Pharmaceuticals Corporation $21.3902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086617391 CMS
Organon Llc $25.0001/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136230908 CMS
ABBVIE INC. $19.9701/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103519194 CMS
Novartis Pharmaceuticals Corporation $22.4701/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086617389 CMS
PBG PUERTO RICO LLC $19.3201/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130949102 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,927.72 73
PY2020 $17,295.40 21
PY2021 $6,936.11 13
PY2022 $8,403.75 25
PY2023 $11,901.33 53
PY2024 $3,010.96 57
PY2025 $2,482.58 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $46,936.00 9
PY2025 Principal investigator $256,279.02 99
PY2024 Recipient $189,454.69 35
PY2024 Principal investigator $238,009.40 77
PY2023 Recipient $86,774.62 28
PY2023 Principal investigator $91,569.79 12
PY2022 Recipient $83,849.16 29
PY2022 Principal investigator $73,241.46 7
PY2021 Recipient $342,872.92 31
PY2021 Principal investigator $42,578.90 16
PY2020 Recipient $402,394.09 33
PY2020 Principal investigator $19,704.41 5
PY2019 Recipient $747,138.22 31
PY2019 Principal investigator $322.09 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

108 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $548.00 12/31/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202535197
Principal investigator 1 ABBVIE INC. $750.00 12/31/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202535199
Principal investigator 1 ABBVIE INC. $200.00 12/11/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530030
Principal investigator 1 ABBVIE INC. $200.00 12/11/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530062
Principal investigator 1 ABBVIE INC. $200.00 12/11/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530064
Principal investigator 1 ABBVIE INC. $195.00 12/10/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529832
Principal investigator 1 ABBVIE INC. $251.00 12/10/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529834
Principal investigator 1 ABBVIE INC. $5,377.61 12/04/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527140
Principal investigator 1 ABBVIE INC. $9,578.10 12/04/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527142
Principal investigator 1 ABBVIE INC. $1,238.30 12/04/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202527344
Principal investigator 1 ABBVIE INC. $500.00 11/25/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202525252
Principal investigator 1 ABBVIE INC. $195.00 11/14/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524349
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,174.01 11/10/2025 Non-covered Recipient Entity
ALMA CRUZ - SANTANA PRIVATE PRACTICE
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312117
Principal investigator 1 ABBVIE INC. $520.00 11/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523227
Principal investigator 1 ABBVIE INC. $520.00 11/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523251
Principal investigator 1 ABBVIE INC. $520.00 11/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523253
Principal investigator 1 ABBVIE INC. $8,915.30 11/05/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521577
Principal investigator 1 ABBVIE INC. $520.00 11/05/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521579
Principal investigator 1 ABBVIE INC. $195.00 11/05/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521759
Principal investigator 1 ABBVIE INC. $23,532.41 11/04/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520297
Principal investigator 1 ABBVIE INC. $6,187.60 10/09/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515697
Principal investigator 1 ABBVIE INC. $1,919.50 10/09/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515699
Principal investigator 1 ABBVIE INC. $260.00 09/17/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202511230
Principal investigator 1 ABBVIE INC. $9,690.00 09/04/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509750
Principal investigator 1 ABBVIE INC. $1,588.00 09/04/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509754
Principal investigator 1 ABBVIE INC. $1,914.30 09/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202508138
Principal investigator 1 ABBVIE INC. $1,422.70 09/03/2025 Non-covered Recipient Entity
GRUPO DERMATOLOGICO CAROLINA
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202508140
Principal investigator 1 ABBVIE INC. $1,177.20 09/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202508142
Principal investigator 1 ABBVIE INC. $1,440.00 08/26/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505843
Principal investigator 1 ABBVIE INC. $251.00 08/26/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505857
Principal investigator 1 ABBVIE INC. $195.00 08/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505477
Principal investigator 1 ABBVIE INC. $94.90 08/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505479
Principal investigator 1 ABBVIE INC. $585.00 08/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505507
Principal investigator 1 ABBVIE INC. $390.00 08/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505509
Principal investigator 1 ABBVIE INC. $1,322.80 08/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503205
Principal investigator 1 ABBVIE INC. $1,562.00 08/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202503207
Principal investigator 1 ABBVIE INC. $25,077.30 08/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503287
Principal investigator 1 ABBVIE INC. $5,196.90 07/02/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202496143
Principal investigator 1 ABBVIE INC. $4,161.41 07/02/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202496151
Principal investigator 1 ABBVIE INC. $273.70 07/02/2025 Non-covered Recipient Entity
GRUPO DERMATOLOGICO CAROLINA
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202496163
Principal investigator 1 ABBVIE INC. $8,614.70 07/02/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496335
Principal investigator 1 ABBVIE INC. $195.00 06/18/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202492319
Principal investigator 1 ABBVIE INC. $195.00 06/18/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202492321
Principal investigator 1 ABBVIE INC. $195.00 06/17/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202491895
Principal investigator 1 ABBVIE INC. $1,588.00 06/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487457
Principal investigator 1 ABBVIE INC. $1,637.40 06/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202489539
Principal investigator 1 ABBVIE INC. $802.80 06/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489775
Principal investigator 1 ABBVIE INC. $604.60 06/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489777
Principal investigator 1 ABBVIE INC. $2,990.10 06/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202489779
Principal investigator 1 ABBVIE INC. $3,655.06 06/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489781
Principal investigator 1 ABBVIE INC. $520.00 05/29/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202486879
Principal investigator 1 ABBVIE INC. $600.00 05/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202485623
Principal investigator 1 ABBVIE INC. $500.00 05/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202485625
Principal investigator 1 ABBVIE INC. $195.00 05/20/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202485473
Principal investigator 1 ABBVIE INC. $195.00 05/20/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202485477
Principal investigator 1 ABBVIE INC. $1,322.80 05/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482835
Principal investigator 1 ABBVIE INC. $2,357.40 05/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202482901
Principal investigator 1 ABBVIE INC. $15,317.80 05/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482903
Principal investigator 1 ABBVIE INC. $1,491.00 05/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202481481
Principal investigator 1 ABBVIE INC. $500.00 05/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202481483
Principal investigator 1 ABBVIE INC. $1,491.00 05/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202481539
Principal investigator 1 ABBVIE INC. $195.00 04/24/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202478984
Principal investigator 1 ABBVIE INC. $390.00 04/24/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202478988
Principal investigator 1 ABBVIE INC. $195.00 04/24/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202479012
Principal investigator 1 ABBVIE INC. $1,395.40 04/03/2025 Non-covered Recipient Entity
GRUPO DERMATOLOGICO CAROLINA
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202469966
Principal investigator 1 ABBVIE INC. $6,846.00 04/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470435
Principal investigator 1 ABBVIE INC. $1,796.65 04/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470439
Principal investigator 1 ABBVIE INC. $1,430.00 04/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202470443
Principal investigator 1 ABBVIE INC. $2,476.60 04/03/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202470602
Principal investigator 1 ABBVIE INC. $1,588.00 03/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459180
Principal investigator 1 ABBVIE INC. $1,430.00 03/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202459385
Principal investigator 1 ABBVIE INC. $3,906.70 03/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202459389
Principal investigator 1 ABBVIE INC. $10,275.50 03/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202459437
Principal investigator 1 ABBVIE INC. $7,001.64 03/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202460449
Principal investigator 1 ABBVIE INC. $750.00 03/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202456575
Principal investigator 1 ABBVIE INC. $273.70 03/06/2025 Non-covered Recipient Entity
GRUPO DERMATOLOGICO CAROLINA
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202456580
Recipient ABBVIE INC. $500.00 02/27/2025 Covered Recipient Physician A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202397885
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,000.45 02/15/2025 Non-covered Recipient Entity
ALMA CRUZ - SANTANA PRIVATE PRACTICE
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312119
Principal investigator 1 ABBVIE INC. $195.00 02/13/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202450904
Principal investigator 1 ABBVIE INC. $200.00 02/13/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202450929
Recipient E.R. Squibb & Sons, L.L.C. $22,551.00 02/13/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1236002305
Recipient ABBVIE INC. $6,599.00 02/11/2025 Covered Recipient Physician A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202397880
Principal investigator 1 ABBVIE INC. $2,037.48 02/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202446764
Principal investigator 1 ABBVIE INC. $7,531.60 02/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202446850
Principal investigator 1 ABBVIE INC. $6,999.20 02/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202447297
Principal investigator 1 ABBVIE INC. $15,511.30 02/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447300
Recipient ABBVIE INC. $967.20 01/22/2025 Covered Recipient Physician A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202397872
Recipient ABBVIE INC. $483.60 01/22/2025 Covered Recipient Physician A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202397876
Principal investigator 1 ABBVIE INC. $195.00 01/21/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202440356
Principal investigator 1 ABBVIE INC. $195.00 01/16/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202439038
Principal investigator 1 ABBVIE INC. $321.68 01/16/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202439042
Principal investigator 1 ABBVIE INC. $195.00 01/16/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202439057
Recipient Novartis Pharmaceuticals Corporation $500.00 01/16/2025 Covered Recipient Physician A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190291142
Recipient Novartis Pharmaceuticals Corporation $6,695.00 01/16/2025 Covered Recipient Physician A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190292731
Principal investigator 1 ABBVIE INC. $195.00 01/15/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202438645
Principal investigator 1 Novartis Pharmaceuticals Corporation $112.90 01/15/2025 Non-covered Recipient Entity
ALMA CRUZ - SANTANA PRIVATE PRACTICE CAIN457A2326
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190307365
Principal investigator 1 ABBVIE INC. $596.70 01/14/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202438213
Recipient Novartis Pharmaceuticals Corporation $3,786.50 01/14/2025 Covered Recipient Physician A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190292727
Recipient ABBVIE INC. $4,853.70 01/09/2025 Covered Recipient Physician A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202397869
Principal investigator 1 ABBVIE INC. $1,250.00 01/08/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA MD
M16-049 - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis No dispute reported 06/30/2026 1202437155
Principal investigator 1 ABBVIE INC. $3,500.00 01/08/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA MD
M16-049 - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis No dispute reported 06/30/2026 1202437159
Principal investigator 1 ABBVIE INC. $548.00 01/08/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202437205
Principal investigator 1 ABBVIE INC. $195.00 01/07/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202436889
Principal investigator 1 ABBVIE INC. $2,500.00 01/06/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202436753
Principal investigator 1 ABBVIE INC. $1,696.40 01/02/2025 Non-covered Recipient Entity
GRUPO DERMATOLOGICO CAROLINA
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202433501
Principal investigator 1 ABBVIE INC. $1,810.90 01/02/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433505
Principal investigator 1 ABBVIE INC. $3,114.80 01/02/2025 Non-covered Recipient Entity
ALMA M CRUZ-SANTANA
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202433509
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,620.72 01/01/2025 Non-covered Recipient Entity
ALMA CRUZ - SANTANA PRIVATE PRACTICE CAIN457A2326
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190307367